The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.

Treatment options should be individualized for patients with relapsed/refractory mantle cell lymphoma (MCL). The selection of optimal second-line therapy depends on the age and fitness of the patients as well as the eligibility for transplant. In the absence of standard management, patients with relapsed/refractory MCL, particularly those who are not eligible for transplant, should be referred for participation in prospective clinical trials investigating novel treatment regimens.